Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
This early-stage startup is working on next-generation immunotherapies. They have already received an accepted IND from the FDA in April 2023. This round is oversubscribed but an allocation has been made specifically for Propel(x) investors!
Join the pitch to get insights about:
The pitch will be followed by a Q&A round where investors can ask questions directly to the startup founders.As per regulations, these calls are for accredited investors only. You will have to register on Propel(x) to confirm your accredited status and risk profile.If you are unable to attend this webinar, register anyway and you will have access to the recording at a later date. After submitting the form, you will be redirected to the Propel(x) investing app to complete your registration.
Disclosure: Private Placements are a high-risk investment. An investment in such offerings is speculative and an investor could experience an entire loss of principal. Past performance may not be indicative of future results. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio.